Meta-Analysis
doi: 10.1111/1753-0407.13182.
Epub 2021 Apr 21.
Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?
Affiliations
- PMID: 33792199
- DOI: 10.1111/1753-0407.13182
Item in Clipboard
Meta-Analysis
Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?
J Diabetes.
2021 Jul.
Abstract
Highlights The beneficial cardiovascular (CV) effects of SGLT-2 inhibitors (SGLT-2i) in patients with heart failure are already known. Whether SGLT-2i exert similar CV effects in heart failure with reduced or preserved ejection fraction is not known. This meta-analysis showed SGLT-2i exert similar CV benefits irrespective of the types of heart failure. Future trials will confirm or refute the CV effects of SGLT-2i in patients with heart failure with preserved ejection fraction.
SGLT-2抑制剂(SGLT-2i)对心力衰竭患者的心血管有益已为人所知。SGLT-2i在射血分数降低或保持不变的心力衰竭患者中是否具有类似的心血管效应尚不清楚。这项meta分析显示，SGLT-2i与心力衰竭的类型无关，具有相似的心血管益处。未来的试验将证实或驳斥SGLT-2i对射血分数保持不变的心力衰竭患者的心血管效应。.
Keywords: SGLT-2 inhibitors; cardiovascular death; heart failure hospitalization; preserved ejection fraction; reduced ejection fraction.
© 2021 Ruijin Hospital, Shanghai JiaoTong University School of Medicine and John Wiley & Sons Australia, Ltd.
Similar articles
-
Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.Diabetes Metab Syndr. 2021 Jan-Feb;15(1):351-359. doi: 10.1016/j.dsx.2021.01.006. Epub 2021 Jan 20. Diabetes Metab Syndr. 2021. PMID: 33503584
-
Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients having reduced ejection fraction heart failure with type 2 diabetes, prediabetes and normoglycemia?Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102282. doi: 10.1016/j.dsx.2021.102282. Epub 2021 Sep 16. Diabetes Metab Syndr. 2021. PMID: 34562869 Review.
-
SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?Curr Atheroscler Rep. 2022 Aug;24(8):627-634. doi: 10.1007/s11883-022-01038-2. Epub 2022 Jun 2. Curr Atheroscler Rep. 2022. PMID: 35653033 Review.
-
SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis.Eur Heart J Cardiovasc Pharmacother. 2022 Sep 3;8(6):557-567. doi: 10.1093/ehjcvp/pvac001. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 35021205
-
Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.Cardiovasc Diabetol. 2021 Apr 22;20(1):83. doi: 10.1186/s12933-021-01272-z. Cardiovasc Diabetol. 2021. PMID: 33888126 Free PMC article.
Cited by
-
Scientific evidence of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction: an umbrella review of systematic reviews and meta-analyses.Front Cardiovasc Med. 2023 May 12;10:1143658. doi: 10.3389/fcvm.2023.1143658. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37252111 Free PMC article. Review.
-
Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions.Heart Fail Rev. 2023 May;28(3):683-695. doi: 10.1007/s10741-021-10186-7. Epub 2021 Nov 1. Heart Fail Rev. 2023. PMID: 34725782 Review.
-
Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.Front Physiol. 2021 Nov 5;12:752370. doi: 10.3389/fphys.2021.752370. eCollection 2021. Front Physiol. 2021. PMID: 34803735 Free PMC article. Review.
-
Meta-analysis of the efficacy and safety of SGLT-2 inhibitors in patients with heart failure and type 2 diabetes mellitus.Medicine (Baltimore). 2025 May 2;104(18):e42196. doi: 10.1097/MD.0000000000042196. Medicine (Baltimore). 2025. PMID: 40324226 Free PMC article.
-
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an overview of 36 systematic reviews.Heart Fail Rev. 2023 Sep;28(5):1033-1051. doi: 10.1007/s10741-023-10324-3. Epub 2023 Jun 7. Heart Fail Rev. 2023. PMID: 37284930 Review.
References
REFERENCES
-
- Fitchett D, Butler J, van de Borne P, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J. 2018;39(5):363-370.
-
- Radholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation. 2018;138(5):458-468.
-
- Kato ET, Silverman MG, Mosenzon O, et al. Effect of Dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019;139(22):2528-2536.
-
- Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of Ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation. 2020;142:2205-2215. https://doi.org/10.1161/CIRCULATIONAHA.120.050255.
-
- Sarraju A, Li J, Cannon CP, et al. Canagliflozin reduces cardiovascular and renal events independent of baseline heart failure: a credence secondary analysis. J Am Coll Cardiol. 2020;75(11):1018.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
